Prediction models for biochemical failure after FS-HDR-BT 163 Characteristic % Missing Initial NCCN risk group, n (%) - Low-risk - Intermediate-risk - High-risk 27 (18.0) 56 (37.3) 59 (39.3) 5.4 ADT use (adjuvant/neo-adjuvant), n (%) 30 (20.0) 0 ADT duration (months), median (IQR) (n = 30) 36.0 (18.0-36.0) 10 nPSA post-primary treatment (ng/mL), median (IQR) 0.56 (0.25-1.10) 3.3 FS-HDR-BT Pre-salvage PSADT (months), median (IQR) 15.7 (11.6-23.6) 0 Interval primary-salvage (months), median (IQR) 97 (63-128) 0 Age at FS-HDR-BT (years), mean (± SD) 71.5 (± 5.0) 0 Pre-salvage PSA (ng/mL), median (IQR) 4.88 (2.80-6.80) 0 Imaging T-stage at FS-HDR-BT, n (%) - T1-2a - T2b-2c - T3a-3b - T4 45 (30.0) 40 (26.7) 63 (42.0) 2 (1.3) 0 Gleason score at FS-HDR-BT, n (%) - 3 + 3 = 6 - 3 + 4 = 7 - 4 + 3 = 7 - Sum score = 8 - Sum score = 9 or 10 14 (9.3) 27 (18.0) 21 (14.0) 6 (4.0) 14 (9.3) 45.4 Tumour location, n (%) - Base - Midgland - Apex - Combination base/midgland/apex - Seminal vesicle - Prostate body and seminal vesicle 21 (14.0) 29 (19.3) 21 (14.0) 31 (20.7) 23 (15.3) 25 (16.7) 0 Seminal vesicle involvement at FS-HDR-BT, n (%) 48 (32.0) 0 GTV at FS-HDR-BT (cm3), median (IQR) 3.0 (1.7-5.1) 0.7 CTV at FS-HDR-BT (cm3), median (IQR) 8.5 (6.0-12.8) 0 Prostate volume at FS-HDR-BT (cm3), median (IQR) 31.4 (25.7-39.6) 0 D95% CTV (Gy), median (IQR) 18.8 (17.4-19.7) 0 V200% CTV (%), median (IQR) 26.3 (18.4-27.9) 0 Post-salvage nPSA (ng/mL), median (IQR) 0.76 (0.26-1.30) 0 Post-salvage time to nPSA (months), median (IQR) 6.1 (3.6-9.6) 0 Percentage PSA reduction (%), median (IQR) 84.2 (68.3-92.9) 0 Biochemical recurrence, n (%) 61 (40.7) 0 Follow-up time (months), median (IQR) 25.1 (13.5-36.1) 0 Table 1 (Continued) – Baseline patient-, tumour-, and treatment-related characteristics. Legend: IQR = Interquartile range. SD = Standard deviation. NCCN = National Comprehensive Cancer Network. ADT = Androgen deprivation therapy. PSA = Prostate-specific antigen. nPSA = PSA nadir. FS-HDR-BT = Focal salvage high-dose-rate brachytherapy. PSADT = PSA-doubling time. GTV = Gross Tumour Volume. D95% = Dose to 95% of the volume. V200% = Volume receiving 200% or more of the prescribed dose. CTV = Clinical Target Volume. 8
RkJQdWJsaXNoZXIy MTk4NDMw